Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of trastuzumab deruxtecan in HER2-mutant advanced non-small cell lung cancer with asymptomatic brain metastases
KCT0009147Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0009147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009147.